Prioritization of Therapeutic Targets for Cancers Using Integrative Multi-omics Analysis

Overview

Journal Hum Genomics

Publisher Biomed Central

Specialty Genetics

Date 2024 Apr 24

PMID 38659038

Authors

Xin Jin

Yunyun Mei

Puyu Yang

Runze Huang

Haifeng Zhang

Yibin Wu

Miao Wang

Xigan He

Ziting Jiang

Weiping Zhu

Lu Wang

Affiliations

Soon will be listed here.

Abstract

Background: The integration of transcriptomic, proteomic, druggable genetic and metabolomic association studies facilitated a comprehensive investigation of molecular features and shared pathways for cancers' development and progression.

Methods: Comprehensive approaches consisting of transcriptome-wide association studies (TWAS), proteome-wide association studies (PWAS), summary-data-based Mendelian randomization (SMR) and MR were performed to identify genes significantly associated with cancers. The results identified in above analyzes were subsequently involved in phenotype scanning and enrichment analyzes to explore the possible health effects and shared pathways. Additionally, we also conducted MR analysis to investigate metabolic pathways related to cancers.

Results: Totally 24 genes (18 transcriptomic, 1 proteomic and 5 druggable genetic) showed significant associations with cancers risk. All genes identified in multiple methods were mainly enriched in nuclear factor erythroid 2-related factor 2 (NRF2) pathway. Additionally, biosynthesis of ubiquinol and urate were found to play an important role in gastrointestinal tumors.

Conclusions: A set of putatively causal genes and pathways relevant to cancers were identified in this study, shedding light on the shared biological processes for tumorigenesis and providing compelling genetic evidence to prioritize anti-cancer drugs development.

Citing Articles

Mechanisms and technologies in cancer epigenetics.

Sherif Z, Ogunwobi O, Ressom H Front Oncol. 2025; 14:1513654.

PMID: 39839798 PMC: 11746123. DOI: 10.3389/fonc.2024.1513654.

Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside.

Cakan E, Lara O, Szymanowska A, Bayraktar E, Chavez-Reyes A, Lopez-Berestein G Cancers (Basel). 2024; 16(17).

PMID: 39272802 PMC: 11394571. DOI: 10.3390/cancers16172940.

References

Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx B . Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016; 48(3):245-52. PMC: 4767558. DOI: 10.1038/ng.3506. View

Rojo de la Vega M, Chapman E, Zhang D . NRF2 and the Hallmarks of Cancer. Cancer Cell. 2018; 34(1):21-43. PMC: 6039250. DOI: 10.1016/j.ccell.2018.03.022. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Hansen R, Saebo M, Furu Skjelbred C, Andersen Nexo B, Hagen P, Bock G . GPX Pro198Leu and OGG1 Ser326Cys polymorphisms and risk of development of colorectal adenomas and colorectal cancer. Cancer Lett. 2005; 229(1):85-91. DOI: 10.1016/j.canlet.2005.04.019. View

Weinberg F, Hamanaka R, Wheaton W, Weinberg S, Joseph J, Lopez M . Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010; 107(19):8788-93. PMC: 2889315. DOI: 10.1073/pnas.1003428107. View

Alexandrov L, Kim J, Haradhvala N, Huang M, Ng A, Wu Y . The repertoire of mutational signatures in human cancer. Nature. 2020; 578(7793):94-101. PMC: 7054213. DOI: 10.1038/s41586-020-1943-3. View

Men T, Zhang X, Yang J, Shen B, Li X, Chen D . The rs1050450 C > T polymorphism of GPX1 is associated with the risk of bladder but not prostate cancer: evidence from a meta-analysis. Tumour Biol. 2013; 35(1):269-75. DOI: 10.1007/s13277-013-1035-1. View

Gaziano L, Giambartolomei C, Pereira A, Gaulton A, Posner D, Swanson S . Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med. 2021; 27(4):668-676. PMC: 7612986. DOI: 10.1038/s41591-021-01310-z. View

10.

Tao S, Rojo de la Vega M, Chapman E, Ooi A, Zhang D . The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol Carcinog. 2017; 57(2):182-192. PMC: 5760364. DOI: 10.1002/mc.22745. View

11.

Reay W, Cairns M . Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet. 2021; 22(10):658-671. DOI: 10.1038/s41576-021-00387-z. View

12.

Zhang J, Dutta D, Kottgen A, Tin A, Schlosser P, Grams M . Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022; 54(5):593-602. PMC: 9236177. DOI: 10.1038/s41588-022-01051-w. View

13.

Zhu Z, Zhang F, Hu H, Bakshi A, Robinson M, Powell J . Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016; 48(5):481-7. DOI: 10.1038/ng.3538. View

14.

Hu J, Zhou G, Wang N, Wang Y . GPX1 Pro198Leu polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010; 124(2):425-31. DOI: 10.1007/s10549-010-0841-z. View

15.

Finan C, Gaulton A, Kruger F, Lumbers R, Shah T, Engmann J . The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017; 9(383). PMC: 6321762. DOI: 10.1126/scitranslmed.aag1166. View

16.

Wouters O, Mckee M, Luyten J . Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020; 323(9):844-853. PMC: 7054832. DOI: 10.1001/jama.2020.1166. View

17.

Martinez-Reyes I, Chandel N . Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10):669-680. DOI: 10.1038/s41568-021-00378-6. View

18.

Harrison R . Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov. 2016; 15(12):817-818. DOI: 10.1038/nrd.2016.184. View

19.

Cohen J, Boerwinkle E, Mosley Jr T, Hobbs H . Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354(12):1264-72. DOI: 10.1056/NEJMoa054013. View

20.

Plenge R, Scolnick E, Altshuler D . Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013; 12(8):581-94. DOI: 10.1038/nrd4051. View